Oppenheimer & Co’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-8,661
| Closed | -$290K | – | 1829 |
|
|
2026
Q1 | $290K | Sell |
8,661
-86
| -1% | -$3.37K | ﹤0.01% | 1411 |
|
|
2025
Q4 | $405K | Sell |
8,747
-101
| -1% | -$5.54K | 0.01% | 1155 |
|
|
2025
Q3 | $598K | Buy |
8,848
+5,598
| +172% | +$415K | 0.01% | 1116 |
|
|
2025
Q2 | $272K | Sell |
3,250
-3
| -0.1% | -$225 | ﹤0.01% | 1396 |
|
|
2025
Q1 | $232K | Buy |
+3,253
| New | +$158K | ﹤0.01% | 1391 |
|
|
2022
Q3 | – | Sell |
-6,537
| Closed | -$18K | – | 1456 |
|
|
2022
Q2 | $18K | Sell |
6,537
-8,934
| -58% | -$24.7K | ﹤0.01% | 1390 |
|
|
2022
Q1 | $52K | Sell |
15,471
-4,587
| -23% | -$23.8K | ﹤0.01% | 1436 |
|
|
2021
Q4 | $123K | Sell |
20,058
-22,551
| -53% | -$237K | ﹤0.01% | 1433 |
|
|
2021
Q3 | $591K | Buy |
42,609
+371
| +0.9% | +$5.17K | 0.01% | 951 |
|
|
2021
Q2 | $722K | Buy |
42,238
+27,937
| +195% | +$472K | 0.01% | 872 |
|
|
2021
Q1 | $270K | Buy |
14,301
+10,256
| +254% | +$331K | 0.01% | 1227 |
|
|
2020
Q4 | $117K | Buy |
4,045
+30
| +0.7% | +$866 | ﹤0.01% | 1301 |
|
|
2020
Q3 | $151K | Sell |
4,015
-73
| -2% | -$2.13K | ﹤0.01% | 1197 |
|
|
2020
Q2 | $136K | Buy |
4,088
+67
| +2% | +$2.9K | ﹤0.01% | 1172 |
|
|
2020
Q1 | $144K | Buy |
+4,021
| New | +$171K | ﹤0.01% | 1079 |
|
Oppenheimer & Co's SLNO Position: Q2 2026 in Review
Oppenheimer & Co sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 8,661 shares — an estimated $290K sold.
Oppenheimer & Co first reported a position in SLNO in Q1 2020 and held it in 15 quarters. The position peaked at $722K in Q2 2021. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Oppenheimer & Co reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Oppenheimer & Co sold 8,661 Soleno Therapeutics shares in Q2 2026, an estimated $290K.
- Oppenheimer & Co first reported a position in Soleno Therapeutics in Q1 2020 and held it in 15 quarters.
- Oppenheimer & Co's Soleno Therapeutics position peaked at $722K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.